If there is a LIF / IL-6 axis in MS – as suggested by the evidence listed in Table 1 – then LIF's role in promoting reparative remyelination provides a route to treat both autoimmunity and demyelination in MS. The gene discussed is LIF; the disease is Autoimmunity.